Table 2.
Clinical characteristics and laboratory results of patients with mpox (N = 155).
| Mpox positive (N = 155) | Mpox negative (N = 51) | Univariable OR | Multivariable OR | |||
|---|---|---|---|---|---|---|
| Duration of symptoms at clinic visit in days – median (IQR) | 7.0 | (4.75–10.0) | 6.5 | (2.75–13.3) | 0.97 (0.95–0.98) | 0.97 (0.95–0.98) |
| Systemic symptoms - | ||||||
| No – n (%) | 39 | (25.2) | 25 | (49.0) | Reference | Reference |
| Yes – n (%) | 116 | (74.8) | 26 | (51.0) | 2.86 (1.48–5.55) | 1.54 (0.65–3.58) |
| Fever or shivers – n/N (%) | 94/116 | (81.0) | 17/26 | (65.4) | - | - |
| Fatigue – n/N (%) | 62/116 | (53.4) | 20/26 | (76.9) | - | - |
| Myalgia – n/N (%) | 49/116 | (42.2) | 11/26 | (42.3) | - | - |
| Headache – n/N (%) | 35/116 | (30.2) | 9/26 | (34.6) | - | - |
| Backpain – n/N (%) | 13/116 | (11.2) | 1/26 | (3.8) | - | - |
| Arthralgia – n/N (%) | 10/116 | (8.6) | 1/26 | (3.8) | - | – |
| Lymphadenopathy - n (%) | ||||||
| No | 83 | (53.5) | 44 | (86.3) | Reference | Reference |
| Yes | 72 | (46.5) | 7 | (13.7) | 5.45 (2.45–13.92) | 3.79 (1.44–11.49) |
| Skin lesions | ||||||
| Absent – n (%) | 10 | (6.5) | 8 | (15.7) | Reference | Reference |
| Present – n (%) | 145 | (93.5) | 43 | (84.3) | 2.70 (0.97–7.27) | 4.35 (1.15–17.57) |
| Number of skin lesions – n/N (%) | Not calculated | Not calculated | ||||
| 1-4 | 52/145 | (35.9) | 19/43 | (44.2) | - | - |
| 5-25 | 78/145 | (53.8) | 19/43 | (44.2) | - | - |
| 26-100 | 14/145 | (9.7) | 2/43 | (4.7) | – | – |
| > 100 | 1/145 | (0.7) | 0 | (0) | – | – |
| Unknown | 0 | (0) | 3/43 | (7.0) | – | – |
| Location of skin lesions – n/N (%) | Not calculated | Not calculated | ||||
| Genital | 81/145 | (55.9) | 15/43 | (34.9) | - | - |
| Penis | 57/145 | (39.3) | 9/43 | (20.9) | - | - |
| Pubis | 28/145 | (19.3) | 3/43 | (7.0) | - | - |
| Scrotum | 35/145 | (24.1) | 5/43 | (11.6) | - | - |
| Perianal or butt cheeks | 58/145 | (40.0) | 11/43 | (25.6) | - | - |
| Perianal | 47/145 | (32.4) | 8/43 | (18.6) | - | - |
| Butt cheeks | 19/145 | (13.1) | 5/43 | (11.6) | - | - |
| Lips or oral cavity | 22/145 | (15.2) | 3/43 | (7.0) | - | - |
| Oral cavity | 11/145 | (7.6) | 2/43 | (4.7) | - | - |
| Lips | 11/145 | (7.6) | 2/43 | (4.7) | - | - |
| Face | 39/145 | (26.9) | 6/43 | (14.0) | – | – |
| Head | 4/145 | (2.8) | 0/43 | (0) | – | – |
| Trunk | 49/145 | (33.8) | 8/43 | (18.6) | – | – |
| Extremities | 63/145 | (43.4) | 15/43 | (34.9) | – | – |
| Palms/soles | 26/145 | (17.9) | 5/43 | (11.6) | – | – |
| Number of affected anatomical sites– median (IQR)a | 2.0 | (1.0–3.0) | 1.0 | (1.0–2.0) | - | - |
| Local manifestations -n (%) | ||||||
| Proctitis | 50 | (32.3) | 3 | (5.9) | 7.62 (2.62–32.40) | 9.41 (2.72–47.07) |
| Urethritis | 12 | (7.7) | 3 | (5.9) | 1.34 (0.41–6.07) | 1.69 (0.37–9.84) |
| Tonsillitis | 2 | (1.3) | 1 | (2.0) | 0.65 (0.06–14.24) | 0.42 (0.02–12.74) |
| Throat pain | 18 | (11.6) | 6 | (11.8) | 0.99 (0.39–2.85) | 1.40 (0.42–5.39) |
| Cough | 5 | (3.2) | 0 | (0) | Not calculated | Not calculated |
| Complications – n (%) | ||||||
| Bacterial skin infection | 13 | (8.4) | 2 | (3.9) | 2.24 (0.59–14.67) | 3.09 (0.63–23.74) |
| Penile oedema with or without paraphimosis | 4 | (2.6) | 1 | (2.0) | 1.32 (0.19–26.23) | 0.92 (0.10–20.72) |
| WHO performance status at visit clinic -n (%) | ||||||
| 0 or 1 | 145 | (93.5) | 48 | (94.1) | Reference | Reference |
| 2 or 3 | 10 | (6.5) | 3 | (5.9) | 1.10 (0.32–5.07) | 1.54 (0.35–8.60) |
| 4 | 0 | (0) | 0 | (0) | – | – |
| Hospitalized -n (%) | 2 | (1.3) | 0 | (0) | Not calculated | Not calculated |
| Severe diseaseb- n (%) | 35 | (22.6) | 6 | (11.8) | Not calculated | Not calculated |
Note: Denominator is the total number of participants unless otherwise specified.
Abbreviations: WHO: World Health organization.
a
Eight anatomical sites: genital region, perianal or butt cheeks, lips or oral cavity, face, head, trunk, extremities and palms or soles.
b
Severe disease: either being hospitalized, being unable to carry out daily activities (who performance status >1), having over 100 skin lesions, severe proctitis requiring opioid analgesics, or complications (severe penile oedema, paraphimosis, severe penile oedema, bacterial superinfection).